Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

2,000

Employees2,000

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

2,000

Employees2,000

NBIX Key Statistics

Market cap

15.19B

Market cap15.19B

Price-Earnings ratio

21.98

Price-Earnings ratio21.98

Dividend yield

—

Dividend yield—

Average volume

952.09K

Average volume952.09K

High today

$151.50

High today$151.50

Low today

$149.00

Low today$149.00

Open price

$150.34

Open price$150.34

Volume

1.02M

Volume1.02M

52 Week high

$186.12

52 Week high$186.12

52 Week low

$122.14

52 Week low$122.14

Stock Snapshot

Neurocrine(NBIX) stock is priced at $150.80, giving the company a market capitalization of 15.19B. It carries a P/E multiple of 21.98.

As of 2026-09-17, Neurocrine(NBIX) stock has fluctuated between $149.00 and $151.50. The current price stands at $150.80, placing the stock +1.2% above today's low and -0.5% off the high.

Neurocrine(NBIX) shares are trading with a volume of 1.02M, against a daily average of 952.09K.

During the past year, Neurocrine(NBIX) stock moved between $122.14 at its lowest and $186.12 at its peak.

NBIX News

Investing.com 19h

Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock - Investing.com

...

Simply Wall St 2d

Is Neurocrine Biosciences Still Undervalued As It Heads Into September Conferences?

Neurocrine Biosciences (NBIX) is stepping into a dense September investor circuit, with back to back presentations scheduled at healthcare conferences hosted by...

TipRanks 6d

Neurocrine price target raised to $183 from $182 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $183 from $182 and keeps an Equal Weight rating on the shares. The firm identifies NBIP-21...

Analyst ratings

87%

of 31 ratings

Buy

87.1%

Hold

12.9%

Sell

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.